2023
Dose-Volume Predictors of Radiation Pneumonitis After Thoracic Hypofractionated Radiation Therapy
Sasse A, Oh P, Saeed N, Yang D, Hayman T, Knowlton C, Peters G, Campbell A, Laird J, Housri N, Park H. Dose-Volume Predictors of Radiation Pneumonitis After Thoracic Hypofractionated Radiation Therapy. Practical Radiation Oncology 2023, 14: e97-e104. PMID: 37984711, DOI: 10.1016/j.prro.2023.11.006.Peer-Reviewed Original ResearchMean lung doseHypofractionated radiation therapyRisk of gradeRadiation pneumonitisLung V20Lung V5Dose-volume predictorsDosimetric risk factorsLogistic regression analysisGrade 5 casesSingle healthcare systemPrimary endpointDose regimensMultivariable analysisLung doseThoracic tumorsDosimetric variablesRisk factorsPneumonitisRadiation therapyCommon treatmentClinical practicePatientsSignificant associationPotential predictors
2020
Using a Collaborative, Virtual Discussion Platform to Mobilize Oncologic Expertise for the COVID-19 Pandemic.
Bejjani A, Burt L, Washington C, Terao M, Housri S, Housri N. Using a Collaborative, Virtual Discussion Platform to Mobilize Oncologic Expertise for the COVID-19 Pandemic. JCO Clinical Cancer Informatics 2020, 4: 794-798. PMID: 32897736, PMCID: PMC7529517, DOI: 10.1200/cci.20.00073.Peer-Reviewed Original ResearchConceptsGynecologic oncologyPediatric oncologyActive disease sitesCOVID-19 pandemicOncology patientsMedical oncologyClinical managementBreast cancerOncology expertsCare resourcesInitial experienceDisease sitesDisease typeOncologyWorldwide pandemicOncologistsRadiation oncologyHealth careCOVID-19Peer-reviewed informationSubstantial numberPandemicTotal numberPatientsCancer
2014
Is There a Role for Postmastectomy Radiation Therapy After Complete Pathologic Response to Neoadjuvant Chemotherapy?
Housri N, Haffty B. Is There a Role for Postmastectomy Radiation Therapy After Complete Pathologic Response to Neoadjuvant Chemotherapy? Current Breast Cancer Reports 2014, 6: 38-44. DOI: 10.1007/s12609-013-0134-8.Peer-Reviewed Original ResearchPathologic complete responsePostmastectomy radiationNeoadjuvant chemotherapySmall primary tumorsAdvanced breast cancerComplete pathologic responseNode-negative diseasePostmastectomy radiation therapyInitial clinical stageTime of mastectomyMulti-institutional trialPatterns of practiceAdvanced diseasePathologic responseComplete responseClinical stagePrimary tumorBreast cancerRadiation therapyRadiation indicationsLower riskPatientsRadiation oncologistsRetrospective dataChemotherapy
2009
Radiotherapy for patients with the human immunodeficiency virus: Are special precautions necessary?
Housri N, Yarchoan R, Kaushal A. Radiotherapy for patients with the human immunodeficiency virus: Are special precautions necessary? Cancer 2009, 116: 273-283. PMID: 20014399, PMCID: PMC3409663, DOI: 10.1002/cncr.24878.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusAntiretroviral therapyImmunodeficiency virusInteraction of HIVImmunodeficiency syndrome (AIDS) epidemicRadiation-associated toxicitiesCourse of radiotherapyManagement of malignanciesHIV patientsMajority of reportsKaposi's sarcomaPatientsRadiotherapyMedical literatureMalignancyAIDSTherapyVirusToxicityReportSpecial precautionsChemoradiotherapySarcomaCancer
2008
Malignant abdominal mesothelioma: Defining the role of surgery
Rodríguez D, Cheung MC, Housri N, Koniaris LG. Malignant abdominal mesothelioma: Defining the role of surgery. Journal Of Surgical Oncology 2008, 99: 51-57. PMID: 18942074, DOI: 10.1002/jso.21167.Peer-Reviewed Original ResearchConceptsRole of surgerySurgical resectionMedian survivalDifferentiated tumor gradePotential surgical resectionOverall median survivalEnd Results (SEER) databaseLonger median survivalLocalized diseaseYounger patientsIndependent predictorsAnnual incidenceResults databasePoor outcomeSurgical extirpationMale genderMalignant mesotheliomaTumor gradeAdvanced ageAbdominal mesotheliomaPatientsMultivariate analysisResectionSurvivalSignificant differencesShould Informed Consent for Cancer Treatment Include a Discussion about Hospital Outcome Disparities?
Housri N, Weil RJ, Shalowitz DI, Koniaris LG. Should Informed Consent for Cancer Treatment Include a Discussion about Hospital Outcome Disparities? PLOS Medicine 2008, 5: e214. PMID: 18942888, PMCID: PMC2570421, DOI: 10.1371/journal.pmed.0050214.Peer-Reviewed Original Research